Skip to main content
. 2011 Jan;13(1):48–56. doi: 10.1016/j.jmoldx.2010.11.001

Table 2.

Tissue of Origin Test Clinical Validation Results

Reference cancer diagnosis Agreement % (ratio) 95% CI Nonagreement % (ratio) 95% CI
Bladder 79.3 (23/29) 60.3–92.0 20.7 (6/29) 8.0–39.7
Breast 96.5 (55/57) 87.9–99.6 3.5 (2/57) 0.4–12.1
Colorectal 91.7 (33/36) 77.5–98.2 8.3 (3/36) 1.8–22.5
Gastric 72.0 (18/25) 50.6–87.9 28.0 (7/25) 12.1–49.4
Hepatocellular 96.0 (24/25) 79.6–99.9 4.0 (1/25) 0.1–20.4
Kidney 89.3 (25/28) 71.8–97.7 10.7 (3/28) 0.3–28.2
Melanoma 84.0 (21/25) 63.9–95.5 16.0 (4/25) 0.5–36.1
Non-Hodgkin's lymphoma 89.7 (26/29) 72.6–97.8 10.3 (3/29) 2.2–27.4
Non-small cell lung 85.2 (23/27) 66.3–95.8 14.8 (4/27) 4.2–33.7
Ovarian 88.9 (40/45) 75.9–96.3 11.1 (5/45) 3.7–24.1
Pancreas 85.7 (24/28) 67.3–96.0 14.3 (4/28) 4.0–32.7
Prostate 96.0 (24/25) 79.6–99.9 4.0 (1/25) 0.1–20.4
Sarcoma 88.9 (24/27) 70.8–97.6 11.1 (3/27) 2.4–29.2
Testicular germ cell 84.0 (21/25) 63.9–95.5 16.0 (4/25) 4.5–36.1
Thyroid 90.3 (28/31) 74.2–98.0 9.7 (3/31) 2.0–25.8
Overall 88.5 (409/462) 85.3–91.3 11.5 (53/462) 8.7–14.7